WuXi’s New Unit Joins Race For Drug Innovation In China
This article was originally published in The Pink Sheet Daily
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.
You may also be interested in...
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.